Ubs Group Ag Contrafect Corp Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.09 - $0.19 $1,596 - $3,370	-17,742 Reduced 60.15%	11,756 $1,000
Q3 2022 Nov 10, 2022	BUY	$0.18 - $3.51 $5,284 - $103,046	29,358 Added 20970.0%	29,498 $5,000
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $960 - $1,333	-301 Reduced 68.25%	140 $1,000
Q2 2021 Aug 13, 2021	SELL	$3.58 - $4.9 $16,675 - $22,824	-4,658 Reduced 91.35%	441 $2,000
Q1 2021 May 12, 2021	SELL	$4.46 - $6.68 $8,121 - $12,164	-1,821 Reduced 26.32%	5,099 $25,000
Q4 2020 Feb 11, 2021	BUY	$5.05 - $6.4 $31,714 - $40,192	6,280 Added 981.25%	6,920 $35,000
Q3 2020 Nov 12, 2020	SELL	$5.05 - $6.99 $18,755 - $25,960	-3,714 Reduced 85.3%	640 $4,000
Q2 2020 Jul 31, 2020	BUY	$4.69 - $7.81 $18,169 - $30,255	3,874 Added 807.08%	4,354 $28,000
Q1 2020 May 01, 2020	BUY	$5.5 - $12.3 $2,640 - $5,904	480 New	480 $3,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.